🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Go APOLLO !! x.com/anup_kasi/stat…

KU Cancer Center Mohammad Jahanzeb Anup Kasi MD MPH Zahra M, PharmD, MBA, BCOP, FHOPA KU Heme Onc Fellowship Lauren Nye @Laurekay4

Proud of my mentee Anusha MD outstanding research work and remarkable achievements

Go APOLLO !!

🎉 Wow, congrats to my amazing mentee for his work on evaluating real-world results of PRRT in GEP-NETs! The significant findings for a unique patient subset are intriguing . So proud to be your mentor, Stijn Hentzen, MD ! 🙌 NET Research Foundation #NETCancer #Carcinoid #GEPNETs #NETsResearch

Excellent session on GI Cancers with Joleen Hubbard, Robert McWilliams (Mayo Clinic), and Anup Kasi MD MPH (The University of Kansas Health System) followed by an engaging Q&A discussion! Very important updates at #BestofASCO in Minneapolis, MN!

Thank you Binay Shah, MD, MHA for the invitation to speak on Upper GI cancers. It was an absolute delight to present at the impeccably organized educational conference #BestOfASCO Beyond Trauma Foundation KU Cancer Center

Had an amazing experience at #GDUGI2023! Engaging in stimulating debate-style discussions was a privilege. Huge thanks to Dr. Cathy Eng and Great Debates for the invitation to share my thoughts! 🗣️🙌

At the 20th #ISGO PER, Eileen M O’Reilly from Memorial Sloan Kettering Cancer Center gave an insightful kickoff presentation on pancreatic cancer #PDAC. Exciting developments on #KRAS targeted therapy for 2023 and beyond. Anup Kasi MD MPH Tanios Bekaii-Saab, MD

We need to think out of the box. Thank you Let's Win Pancreatic Cancer 💜 for highlighting this novel clinical trial that I’m leading with misetionamide GP-2250 in #PancreaticCancer by Panavance #pancsm #PancChat PanCAN letswinpc.org/research/clini…

Pancreatic cancer moving the needle on improved outcomes, every bit counts for these patients. With 5 year OS of 13%, more studies needed. NAPOLI3 trial for journal club today with Anup Kasi MD MPH @smullangiMd #PancreaticCancer #JournalClub

#ASCO24 - At 1:30 pm, head over to Hall A where Anup Kasi MD MPH and the @KUCancerCenter team are presenting “Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosis: Insights from a phase II randomized trial.”

🏁 Excited to share the news that we have completed full enrollment of #PancreaticCancer Cohort of our CENDIFOX Trial - goo.gl/alerts/4TU3F1 Lisata Therapeutics, Inc. KU Cancer Center KU Hospital News PanCAN Let's Win Pancreatic Cancer 💜 #PancSM Chat Looking forward to the results in the near future !

Thank you Binay Shah, MD, MHA for inviting me to discuss #Hepatobiliary and #pancreaticcancer updates from #ASCO24. It was an honor to present at such a well-organized and educational conference. #BestOfASCO @asco2024 Beyond Trauma Foundation #globaloncology KU Cancer Center

Thrilled to speak at the #KUICE_T symposium on the role of #CAR_T in solid tumors! Huge thanks to Al-Ola A Abdallah MD (USMIRC) & Nausheen Ahmed MD for the invitation. The event was incredibly insightful, showcasing the latest in cellular therapeutics for hematology and oncology! KU Cancer Center

The AVENGER 500 trial Phase III global🌐study, investigated the efficacy and safety of adding devimistat to a modified regimen of fluorouracil, oxaliplatin, irinotecan🧪, and leucovorin for treating metastatic pancreatic adenocarcinoma (mPC). The trial involved 528

Dr. Anup Kasi will be presenting at the Visceral Medicine Conference in Leipzig, Germany on Oct. 4. This will be the first presentation of misetionamide (GP-2250) clinical results diving deeper into its Phase 1 trial to evaluate the safety, tolerability, and preliminary efficacy

When a UPMC Hillman Cancer Center Pittsburgh investigator escaped from the East Coast to reconnect with her KU Cancer Center Kansas roots in the heart of the Midwest! SWOG Cancer Research Network #MidwestMagic at Chicago

“We are delighted to complete enrollment in all three cohorts in the CENDIFOX study and are encouraged by certepetide’s potential to improve outcomes for patients with advanced solid tumors. We are eager to analyze the data from each cohort to determine the efficacy of this novel

Distinct molecular and clinical features of KRAS G12 mutations in Pancreatic Cancer oncodaily.com/url/228259 Jash Datta, MD Clinical Cancer Research Anup Kasi MD MPH Emil Lou, MD, PhD, FACP Rachna Shroff, MD, MS, FASCO Mike Pishvaian #Cancer #GIOnc #Pancsm #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology